Ilmarinen Mutual Pension Insurance Co Purchases 8,500 Shares of Merck & Co., Inc. $MRK

Key Points

• Ilmarinen Mutual Pension Insurance Co. increased its Merck stake by 2.0% in Q4, buying 8,500 additional shares and bringing its total holdings to 441,500 shares worth about $46.5 million.
• Several other institutional investors also boosted positions, and institutional ownership of Merck remains high at 76.07% of shares outstanding.
• Merck’s recent news flow was generally positive, including shareholder approval of board nominees, executive pay, and auditor ratification, along with approval of its chicken bronchitis vaccine in China and an upcoming Jefferies healthcare conference appearance.

Ilmarinen Mutual Pension Insurance Co grew its holdings in shares of Merck & Co., Inc. (NYSE:MRK - Free Report) by 2.0% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 441,500 shares of the company's stock after buying an additional 8,500 shares during the quarter. Ilmarinen Mutual Pension Insurance Co's holdings in Merck & Co., Inc. were worth $46,472,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in the stock. Moors & Cabot Inc. raised its stake in shares of Merck & Co., Inc. by 6.2% during the 4th quarter. Moors & Cabot Inc. now owns 97,972 shares of the company's stock worth $10,313,000 after purchasing an additional 5,726 shares in the last quarter. EagleClaw Capital Managment LLC raised its holdings in Merck & Co., Inc. by 0.4% in the 4th quarter. EagleClaw Capital Managment LLC now owns 31,963 shares of the company's stock valued at $3,364,000 after acquiring an additional 120 shares during the period. Investment Partners LTD. lifted its holdings in Merck & Co., Inc. by 2.1% during the 4th quarter. Investment Partners LTD. now owns 5,021 shares of the company's stock worth $529,000 after purchasing an additional 103 shares during the last quarter. Houlihan Financial Resource Group Ltd. acquired a new position in shares of Merck & Co., Inc. in the fourth quarter valued at about $453,000. Finally, Carnegie Lake Advisors LLC grew its position in shares of Merck & Co., Inc. by 2.6% during the 4th quarter. Carnegie Lake Advisors LLC now owns 9,064 shares of the company's stock worth $954,000 after purchasing an additional 232 shares in the last quarter. Institutional investors and hedge funds own 76.07% of the company's stock.

Merck & Co., Inc. News Roundup

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Merck shareholders approved the company’s board nominees, executive pay package, and auditor ratification at its annual meeting, reinforcing governance continuity and removing a potential overhang. Merck Shareholders Back Board, Pay and Auditor Ratification
• Positive Sentiment: Merck announced participation in the Jefferies Global Healthcare Conference, which can spark investor attention if management provides updates on pipeline progress, guidance, or strategic priorities. Merck to Participate in the Jefferies Global Healthcare Conference
• Positive Sentiment: Merck’s chicken bronchitis vaccine was approved for use in China, expanding a potential animal-health opportunity in a large market and adding a modest growth catalyst. Merck chicken bronchitis vaccine approved for use in China
• Neutral Sentiment: Merck congratulated Ontario on expanding pharmacy scope rules, a policy development that is favorable for healthcare access but has no immediate direct financial impact on MRK. Merck Congratulates Ontario Government on Expanding Pharmacy Scope to Help Improve Access to Care
• Neutral Sentiment: Merck remained a heavily watched stock in Zacks coverage and on analyst/market screens, but those mentions were not tied to a new fundamental development. Here is What to Know Beyond Why Merck & Co., Inc. (MRK) is a Trending Stock
• Neutral Sentiment: The company’s upcoming Jefferies appearance and shareholder-call materials may keep attention on the stock, but they do not yet signal a clear change in earnings outlook. Merck & Co., Inc. (MRK) Shareholder/Analyst Call - Slideshow

Wall Street Analysts Forecast Growth

MRK has been the topic of several analyst reports. Barclays started coverage on shares of Merck & Co., Inc. in a research report on Friday, February 20th. They set an "overweight" rating and a $140.00 price target on the stock. JPMorgan Chase & Co. upped their price target on Merck & Co., Inc. from $125.00 to $135.00 and gave the company an "overweight" rating in a research report on Monday, April 6th. Citigroup assumed coverage on shares of Merck & Co., Inc. in a research report on Wednesday, May 6th. They set a "neutral" rating and a $125.00 price objective for the company. Weiss Ratings lowered Merck & Co., Inc. from a "hold (c+)" rating to a "hold (c)" rating in a research note on Friday, May 15th. Finally, Guggenheim increased their price objective on shares of Merck & Co., Inc. from $122.00 to $140.00 and gave the stock a "buy" rating in a research report on Friday, February 6th. One research analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating and seven have assigned a Hold rating to the company's stock. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $128.18.

Merck & Co., Inc. Price Performance

Shares of NYSE:MRK opened at $119.87 on Friday. The company has a current ratio of 1.30, a quick ratio of 1.06 and a debt-to-equity ratio of 1.02. The stock has a market cap of $296.05 billion, a PE ratio of 33.77, a price-to-earnings-growth ratio of 2.71 and a beta of 0.18. The stock's fifty day simple moving average is $116.31 and its two-hundred day simple moving average is $111.41. Merck & Co., Inc. has a 1-year low of $75.40 and a 1-year high of $125.14.

Merck & Co., Inc. (NYSE:MRK - Get Free Report) last posted its earnings results on Thursday, April 30th. The company reported ($1.28) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.47) by $0.19. The firm had revenue of $16.29 billion during the quarter, compared to analyst estimates of $15.85 billion. Merck & Co., Inc. had a net margin of 13.59% and a return on equity of 27.55%. The business's revenue was up 4.9% compared to the same quarter last year. During the same quarter in the prior year, the business posted $2.22 EPS. Merck & Co., Inc. has set its FY 2026 guidance at 5.040-5.160 EPS. As a group, analysts forecast that Merck & Co., Inc. will post 5.16 EPS for the current fiscal year.

Merck & Co., Inc. Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, July 8th. Shareholders of record on Monday, June 15th will be given a $0.85 dividend. This represents a $3.40 dividend on an annualized basis and a yield of 2.8%. The ex-dividend date of this dividend is Monday, June 15th. Merck & Co., Inc.'s dividend payout ratio is presently 95.77%.

About Merck & Co., Inc.

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.